期刊
BLOOD
卷 126, 期 21, 页码 2392-2403出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2015-03-632984
关键词
-
类别
资金
- National Health and Medical Research Council (NHMRC) Biomedical Fellowship
- Peter MacCallum Cancer Foundation
- Fondazione Italiana per la ricerca sul cancro (FIRC)
- National Institutes of Health [CA 174793]
- Burroughs-Wellcome Fund
- Alex's Lemonade Stand Foundation A Award
- NHMRC
- Cancer Council Victoria
- Leukemia Foundation of Australia
- Victorian Cancer Agency
- Australian Rotary Health Foundation
- ERC [36860]
- Special Research Program of the Austrian Science Fund [F4710]
- Boehringer Ingelheim
- Italian Association for Cancer Research
- FIRC
- National Research Council
- European Community [277899]
Histone deacetylase (HDAC) inhibitors (HDACis) have demonstrated activity in hematological and solid malignancies. Vorinostat, romidepsin, belinostat, and panobinostat are Food and Drug Administration approved for hematological malignancies and inhibit class II and/or class I HDACs, including HDAC1, 2, 3, and 6. We combined genetic and pharmacological approaches to investigate whether suppression of individual or multiple Hdacs phenocopied broad-acting H DACis in 3 genetically distinct leukemias and lymphomas. Individual Hdacs were depleted in murine acute myeloid leukemias (MLL-AF9;Nras(G12D); PML-RARet acute promyelocytic leukemia [APL] cells) and E mu-Myc lymphoma in vitro and in vivo. Strikingly, Hdac3-depleted cells were selected against in competitive assays for all 3 tumor types. Decreased proliferation following Hdac3 knockdown was not prevented by BCL-2 overexpression, caspase inhibition, or knockout of Cdknl a in ER-Myc lymphoma, and depletion of Hdac3 in vivo significantly reduced tumor burden. Interestingly, APL cells depleted of Hdac3 demonstrated a more differentiated phenotype. Consistent with these genetic studies, the HDAC3 inhibitor RGFP966 reduced proliferation of ER-Myc lymphoma and induced differentiation in APL. Genetic codepletion of Hdac1 with Hdac2 was pro-apoptotic in ER-Myc lymphoma in vitro and in vivo and was phenocopied by the HDAC1/2specific agent RGFP233. This study demonstrates the importance of HDAC3 for the proliferation of leukemia and lymphoma cells, suggesting that HDAC3-selective inhibitors could prove useful for thetreatment of hematological malignancies. Moreover, our results demonstrate that codepletion of Hdacl with Hdac2 mediates a robust pro-apoptotic response. Our integrated genetic and pharmacological approach provides important insights into the individual or combinations of HDACs that could be prioritized for targeting in a range of hematological malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据